

JW Therapeutics(2126.HK)

2021 Annual Results Presentation

Disclaimer 免责声明

This presentation may contain forward-looking, confidential and/or proprietary information including without limitation to JW Therapeutics' manufacturing process, pipeline, business development and third party collaboration, etc, which are provided on as-is basis, and/or based on management's current expectations, strategies and beliefs as of the date of this presentation, therefore shall not be regarded as commitment or guarantee from JW and/or either of JW Therapeutics' directors.
本演示稿可能包含药明巨诺的前瞻性、保密及/或专有信息，包括但不限于药明巨诺的生产工艺、管线、业务发展和第三方合作等，这些信息基于事实情况提供及/或是管理层在截至本次演示之日的现有期望、策略和信念， 因此不代表公司或任何董事的承诺或保证。

The aforesaid information might be subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described, and be subject to modification or adjustment, from time to time, without prior or further notice. Except as required by law, JW Therapeutics undertakes no obligation to update or revise publicly any information, whether as a result of new information, future events or otherwise, and/or to further explanation.
前述信息在实际运营中可能受一些风险、不确定性和假设的影响，从而导致实际结果在实质上与所描述的有所区别。除法律规定外，我们没有义务公开有关于前述任何信息的更新或修改，无论是由于做出该等陈述之日后出现的新资讯、未来事件或其他原因，亦或是为了反映意外事件的发生，亦没有义务对此进行进一步的解释。

No copying, photocopying, video recording, broadcasting or any adjustment or modification to the contents of this presentation is allowed, without prior written consent of JW Therapeutics.
未经公司事先书面确认，请勿私自进行复制、影印、 录影、传播或对内容进行任何调整或修改。

JW Therapeutics is a leading cell therapy company listed in HKEx (stock code: 2126.HK). A Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of Hong Kong Exchanges and Clearing Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market its products successfully. Shareholders and potential investors of JW Therapeutics are advised to exercise due care when dealing in the shares of JW Therapeutics.
药明巨诺是一家在香港上市的细胞免疫治疗公司(股票代码：2126.HK)。香港交易所证券上市规则第18A.05条规定的警示声明：药明巨诺无法确保药明巨诺将能成功开发及最终成功销售其产品。药明巨诺股东及潜在投资者在买卖药明巨诺股份时务请审慎行事。

Agenda

01 2021 Overview

02 Commercialization Progress

03 Product and Pipeline Updates

04 Financial Overview

05 Strategy for Future and Development

01

2021 Overview



JW Therapeutics – A Leading Cell Therapy Company

A Potential Superior CD19 CAR-T, Carteyva®

- NDA granted priority review by the NMPA
- Potential to achieve **superior safety results and comparable efficacy**
- **The first** CAR-T product approved as a Category 1 biologics product in China, and **sixth** approved CAR-T product globally



Robust Pipeline

- Broad coverage of both **hematological** cancer and **solid tumors**
- Strong **BD** and **in-house R&D** capabilities to continuously enrich pipeline

Best Team and Talent in Cell Therapy

- **Experienced and driven** management team
- **Cross-disciplinary expertise for R&D projects**

End-to-end Platform

- In-house **clinical development**, established **regulatory affairs** with close collaboration with regulators
- Robust **process development** and leading **manufacturing**
- Extending capabilities in **commercialization** and **early research**

2021: A Year Marked a Major Milestone in the History of JW Therapeutics

1st (Carteyva®)
CAR-T therapy as a Category 1 biologics product in China

54
Prescriptions

55.6%
CRR

30.8
Revenue (RMB' million)

Clinical Progress	Commercialization	Operation excellence	Financial Update
■ 2nd indication: 3L FL sNDA submitted	■ Established vein to vein management process for timely and secure deliver	■ Building out of discovery capabilities while pursuing BD opportunities	■ Generated RMB30.8m revenue
■ Trials for other B cell malignancies on track, including r/r MCL sNDA submission planned for 2023, 2L LBCL and pALL IND submitted	■ Covered by 44 insurance product and 16 city-level complementary medical insurance programs	■ Continue high manufacture success rate of 99%	■ 2021 Loss RMB702m, decreased by RMB961.5m compared to 2020
■ Solid tumor development on track: manufacture process development and facility upgrade completed	■ Established with key lymphoma experts the first CAR-T guiding principles to standardize the clinical applications for physicians	■ Successfully laid the foundation for execution of cost reduction to be realized from the second half of 2022	■ RMB1,834m cash balance

Note: CRR 55.6% is from the first 27 assessable commercial patients, according to reports from treating physicians regarding their individual assessment of best response after Carteyva® treatment

Fully Integrated Cell Therapy Innovation and Commercialization Platform

Our uniquely designed and fully integrated capabilities range from early research, and analytical development through process development and clinical development to regulatory affairs, with GMP manufacturing facilities and dedicated commercialization capability

Early Research

- **Strengthen the existing pipeline** through the development of next-generation platforms
- **Engineer new pipeline products** to hematology and solid tumor indications with global right
- **Expand IP portfolio and technical platforms** that enhance the efficacy, robustness and safety of our products

Clinical Development

- **All clinical operations in-house** to ensure quality and execution efficiency
- **Solid clinical development capabilities** proven by successful approval of Carteyva®

Regulatory Affairs

- **Viewed as Key Expert driving the development of China's cell therapy**
- Regularly communicates with CDE
- Provided feedback on the drug administration law and the CAR-T GMP inspection guide

Commercialization

- Dedicated in-house commercial team to market cell therapy products across China
- Establish a whole process management guidance with top KOLs and physicians to ensure a **higher-quality and safety experience for patient**

CMC

- **Strong process development**: have developed a single-train manufacturing process platform that allows us to optimize cell product characteristics and consistency
- Process development capabilities based on internal development and optimization of technology in-licensed from Juno
- **Rigorous analytical development, quality control, and quality assurance**, all functions seamlessly coordinated with one another to support our manufacturing capability

Manufacturing

- Clinical manufacturing at Waigaoqiao and Zhangjiang facilities of approx. 600 sqm
- New **cGMP commercial manufacturing site** in Suzhou covering approx. 10,000 sqm designed to address all of the major challenges associated with scaling up from clinical scale to commercial scale manufacturing

Seasoned Management Team

Experienced Management Team

James Li, M.D.

Chairman, Executive Director and CEO

AMGEN

KLEINER PERKINS

MERCK

Xin Fu

Chief Financial Officer

Pfizer KPMG

Lapyuen Harry Lam, PHD

Chief Technology Officer

SANOFI Genentech A Member of the Roche Group

Mark Gilbert, M.D.

Chief Medical Officer

JUNO THERAPEUTICS

Alex Qiong Wu

Chief Commercial Officer

MERCK Baxter

Raymond J. Hage, Jr.

Corporate *Development*

Lilly NOVAVAX

Shaun Paul Cordoba, PHD

Chief Scientific Officer

Autolus

Karen Xu

Head of Quality

MERCK WuXi Biologics Global Solution Provider

Carol Zhu

Portfolio and Project Management

MERCK gsk GlaxoSmithKline

02

Commercialization Progress



Strong Execution of Commercialization Launch

Quick access to 1st patient

2021.9.1 — NMPA Approval

2021.9.3 — NMPA Announcement

1st Prescription

1st Commercial Order

2021.9.8 — **1st APH**
5 days after announcement

2021.10.3 — **1st Infusion**
1 month after approval

Quick to gain market

54 Prescriptions in 2021

30 Infusions in 2021

Clear Product Positioning and Commercialization Strategy Lead to Successful Launch and Laid the Foundation of Future Growth

BIC Product Positioning

Better efficacy, Better safety

SOLO



Solid Commercialization Strategy

Professor Wu
The Frist Affiliated Hospital of Soochow University

"Carteyva®'s successful launch has brought a brand-new treatment choice for R/R LBCL patients and is also a milestone in the development of innovative drugs in China"

Professor Zhou
Wuhan Tongji Hospital

"Carteyva® has actually presented distinguished advantage in safety in real cases. Patients felt no much pain during the whole treatment"

Professor Song
Beijing Cancer Hospital

"Long-time disease free survival is the ultimate goal for both physicians and patients. 76.8% 1-year OS rate that Carteyva® demonstrated in Reliance study is quite a satisfying result"

Eco-system of Whole Process Management to Serve Patients

Build Eco-system to Provide First-class Service

Vein to vein process



CAR-T consultant

Innovative payment

Guidance Principle

白血病·淋巴瘤 2022年1月第31卷第1期 Journal of Leukemia & Lymphoma, January 2022, Vol. 31, No. 1

瑞基奥仑赛注射液临床应用指导原则（2021年版）

中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 中华医学会血液学分会 中国医师协会血液科医师分会

通信作者：马军，哈尔滨血液病肿瘤研究所，哈尔滨 150010，Email：majun0322@126.com；朱军，北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142，Email：zhu-jun2017@outlook.com

Support Strategic Partners to Serve Patients

Onsite Training

Hospital Certification

Dry-run

Multi-disciplinary treatment Platform

Completed training, dry-run and certification of

61 top hematology hospitals in China

55.6% CRR among first 27 assessable commercial patients, similar to registrational clinical trial result (51.7%)

Establish a Multi-layer Medical Care System for CAR-T Treatment to Improve Patient Affordability

STEP 1

Innovative Payment

1	2	3
Pay for performance insurance	AE insurance	Interest-free Installment loan

药明巨诺 JW Therapeutics × MediTrust 镁信健康 Health

STEP 2

Commercial Insurance

City-level supplementary insurance	Million medical insurance	High-end insurance	Single disease insurance

中国平安 PINGAN 金融·科技 | PICC 中国人保 | CHINA LIFE P&C 中国人寿财险 | AIA 友邦保险 | 太平洋保险 CPIC | MSH CHINA | 泰康 Taikang 保险 资管 医养 | Cigna | 富德生命人寿 FUNDE SINO LIFE | Bupa | 交银康联人寿 BoComm Life | 众安保险 | 水滴保 水滴保·保你省

44 commercial insurance

16 city level supplementary insurance

1st 100% refund from insurance was received by patient from Hangzhou on Feb 21st

STEP 3

Charitable Platform

Charities aid foundation	Crowd-funding

水滴汇聚基金会 | 腾讯公益 GONGYI.QQ.COM | 水滴筹 | 轻松筹 Fun in funding

03

Product and Pipeline Updates

Our Robust and Differentiated Cell Therapy Pipeline

	Product	Target	Indication	Commercial Rights	NMPA Classification	Partner
Hematologic Malignancies	JWCAR029 / Relmacabtagene Autoleucel (relma-cel) **[1]	CD19	3L LBCL	Mainland China, Hong Kong, Macau*	Category 1	JUNO Bristol Myers Squibb Company
			3L FL	Mainland China, Hong Kong, Macau*		
			3L MCL	Mainland China, Hong Kong, Macau*		
			2L LBCL	Mainland China, Hong Kong, Macau*		
			3L ALL	Mainland China, Hong Kong, Macau*		
			3L CLL	Mainland China, Hong Kong, Macau*		
	JWCAR129[2]	BCMA	r/r MM	Mainland China, Hong Kong, Macau*	Category 1	JUNO Bristol Myers Squibb Company
	Nex-G	CD19	NHL	Mainland China, Hong Kong, Macau*	Category 1	JUNO Bristol Myers Squibb Company
Solid Tumors	JWATM203	AFP	HCC	Mainland China, Hong Kong, Macau, Taiwan, and member countries of ASEAN*	Category 1	EUREKA
	JWATM213[3]	AFP	HCC	Mainland China, Hong Kong, Macau, Taiwan, and member countries of ASEAN*	Category 1	EUREKA Lyell
	JWATM204	GPC3	HCC	Mainland China, Hong Kong, Macau, Taiwan , and member countries of ASEAN*	Category 1	EUREKA
	JWATM204	GPC3	Basket	Mainland China, Hong Kong, Macau, Taiwan , and member countries of ASEAN*	Category 1	EUREKA
	JWATM214[3]	GPC3	HCC	Mainland China, Hong Kong, Macau, Taiwan, and member countries of ASEAN*	Category 1	EUREKA Lyell



Abbreviations: LBCL = large B-cell lymphoma; FL = follicular lymphoma; MCL = mantle cell lymphoma; ALL = acute lymphoblastic leukemia; CLL = chronic lymphocytic leukemia; MM = multiple myeloma; NHL = non-Hodgkin lymphoma; HCC = hepatocellular carcinoma; NSCLC = non-small cell lung cancer; AFP = alpha-fetoprotein; GPC3 = glypican-3; r/r = relapsed or refractory; 3L = third-line; 2L = second-line; Basket=Basket Design, A variety of solid tumors were included

* Mainland China, Hong Kong, Macau and Taiwan refer to Mainland China, Hong Kong (China), Macau (China) and Taiwan (China), respectively.

** Denotes a Core Product Candidate.

1. Relma-cel is based on the same CAR construct as the product lisocabtagene maraleucel (Breyanzi or lisocabtagene or liso-cel) of Juno Therapeutics, which was approved by the U.S. Food and Drug Administration in February 2021.
2. JWCAR129 is based on the same CAR construct as Juno Therapeutics' product orvacabtagene autoleucel (orva-cel).
3. Developing using Lyell technology.
4. JWATM204 is in a Phase I investigator-initiated trial in China. Eureka's products based on the CAR constructs underlying JWATM203 and JWATM204 are currently in Phase I/II trials in the US conducted by Eureka under an IND application. In November 2021, the U.S. FDA granted Fast Track Designation to Eureka's counterpart to JWATM203 for the treatment of hepatoblastoma ("HB") and HCC in pediatric patients, as well as "rare pediatric disease designation" for the treatment of HB. In February 2022, the FDA granted Orphan Drug Designation to Eureka's counterparts to JWATM203 and JWATM 204.

Carteyva®: Potential Superior Anti-CD19 CAR-T Product

- The **first CAR-T therapy approved as a Category 1 biologics** product in China
- In the registrational Phase II clinical trial, Carteyva® demonstrated **superior safety results with comparable efficacy**

Comparable Efficacy[1]

** Not from a head-to-head comparison study*

	ORR	CRR
Carteyva®	**77.6%**	**51.7%**

Marketed CAR-T

	ORR	CR
Yescarta	72%	51%
Kymriah	50%	32%
Breyanzi	73%	54%

Superior Safety Profile[1]

** Not from a head-to-head comparison study*

	Indication	NT (Any)	sNT (≥Grade 3)	CRS (Any)	sCRS (≥Grade 3)
Carteyva®	**r/r LBCL**	**20.3%**	**3.4%**	**47.5%**	**5.1%**

Marketed CAR-T

	Indication	NT (Any)	sNT (≥Grade 3)	CRS (Any)	sCRS (≥Grade 3)
Yescarta	r/r LBCL	87%	31%	94%	13%
Kymriah	r/r LBCL	58%	18%	74%	23%
Breyanzi	r/r LBCL	35%	12%	46%	4%

Excellent long-term efficacy: 1Y OS 76.8%

The median follow-up time: 17.9 months, the median OS was not reached



The excellent 1 year OS rate and trend of OS KM curve indicate the "curing" potential of Carteyva®.

Source:
[1] All clinical data above comes from specification of each marketed product, the data of Carteyva® is as the end of December 31, 2020

.Abbreviations: ORR=Overall Response Rate；CRR=Compete Response Rate；NT=Neurotoxicity；sNT=severe Neurotoxicity；CRS=Cytokine Release Syndrome；sCRS=severe Cytokine Release Syndrome；; r/r = relapsed or refractory；LBCL = large B-cell lymphoma

Carteyva® Expected to Be The First CAR-T Product Approved for Treatment of 3L FL Patient in China

- **Granted Breakthrough Therapy Designation by the NMPA in September 2020**
- **Ph2 pivotal trial has completed in mid-2021**
- **sNDA application was accepted by NMPA in Q1 2022**

Efficacy Comparison

** Not from a head-to-head comparison study*

	ORR	CRR
Carteyva®	**100%**	**92.6%**

	ORR	CRR
Yescarta	91%	60%
Kymriah	86%	69%

Safety Profile Comparison

** Not from a head-to-head comparison study*

	Indication	NT (Any)	sNT (≥Grade 3)	CRS (Any)	sCRS (≥Grade 3)
Carteyva®	**3L FL**	**18%**	**4%**	**43%**	**0**

	Indication	NT (Any)	sNT (≥Grade 3)	CRS (Any)	sCRS (≥Grade 3)
Yescarta	3L FL	77%	21%	84%	8%
Kymriah	3L FL	4%	1%	49%	0

Source: data from ASH 2021 and product specification of Yescarta

Abbreviations: ORR=Overall Response Rate；CRR=Compete Response Rate ；NT=Neurotoxicity；sNT=severe Neurotoxicity；CRS=Cytokine Release Syndrome；sCRS=severe Cytokine Release Syndrome；r/r = relapsed or refractory；FL = follicular lymphoma；3L=third line

Carteyva®: Exploring the Further Clinical Potential in Early Line Treatment and Other Indications

- **To fully explore the clinical potential of Carteyva®, we intend to develop Carteyva® for a number of other hematological indications, including second-line LBCL ,MCL, pALL and CLL**

2nd line LBCL

- A multi-center, randomized Phase II registrational clinical trial comparing Carteyva® to 2nd line stand of care therapy
- Aim to establish new standard of care and impact clinical practice for 2nd line LBCL population
- **IND approval is expected in Q2 2022 and FPI in Q3 2022**

MCL

- Historically has been resistant to standard therapy, or therapies have provided only short periods of response
- **Single arm Ph2 pivotal trial started, patient enrollment expected to complete in 4Q2022**
- Will evaluate MCL patients for whom the use of BTK inhibitors has failed

pALL

- Relapse after initial induction chemotherapy carries a very poor prognosis with median survival rates in adults being less than one year
- **First registration trial to execute in pediatric population**
- **IND approval and first patient enrollment expected to occur in 2Q 2022**

CLL

- Certain subtypes of CLL have a much worse prognosis
- Will evaluate high risk CLL patients for whom the use of BTK inhibitors has failed
- **To commence a single arm Ph1/2 trial in 2022**

JWATM204 and JWATM214 Programs

Overview

JWATM204: A novel TCR-T therapy tests on GPC3 target that potentially benefit many HCC patients and other solid tumor patients , developed using ARTEMIS 3.0 technology , JWATM214 are developed using ARTEMIS 3.0 technology combined with the Lyell technology

Mechanism of Action



Our Advantages

✓ **GPC3** expressed in **~80% HCC patients** and also high expression in other solid tumors including subtype of gastric cancer and NSCLC
Use of ARTEMIS technology could potentially create **more effective and safer** T-cell therapy
Combination of Lyell's technology for JWATM214 may increase T-cell functionality and reduce T-cell exhaustion

Our Clinical Development Plan

- A Ph I dose escalation study will initiated in late stage HCC patient to confirm safety profile and recommended dose of JWATM204 for Ph 2 study. FPI is expected during Q2, 2022
- Another phI dose escalation study will also initiated in solid tumor patients to identify alternative indications. FPI is expected during Q3 2022
- Further development plan is to expand to earlier lines of treatment of HCC as either monotherapy or combinations of TKI and CPI agents, and conduct pivotal studies in other solid tumor type.

2021				2022			
Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4

- CMC process lock
- Manufactory ready and FPI for HCC ph I study
- FPI for basket design ph I study

04

Financial Overview



Key Financial Update

Revenue

(RMB million)



Operating expenses

(RMB million)



Loss for the year

(RMB million)

Cash and cash equivalents

(RMB million)



Manufacturing & Technology Evolution - from Cost Reduction to Value Creation

Near-Term
1 – 2 years

Realize significant cost reduction by implementing **technologies and procedures to reduce raw material wastes and scraps**

Mid-Term
2 – 3 years

Realize **further cost reduction** by replacing imported materials with **domestic supplies**



Long-Term
3 – 5 years

Implement new technologies to simplify and/or replace/combine unit operations and enable the **next generation** CAR-T product with:

- High quality
- Better product characterization
- Improved product efficacy and safety
- Lower cost
- Shorter production cycle

05

Strategy for Future and Development



Our Strategies

- Drive full-scale commercialization of Carteyva® and build upon our significant first mover advantage
- Solidify our leadership in hematological cancers by continuing to develop Carteyva® for earlier lines of treatment and additional indications, as well as clinical development of other new products
- Leverage our integrated cell therapy platform to expand into the emerging solid tumor market
- Continuously enhance our manufacturing capability and reduce cost through innovation and scale
- Grow our business through in-licensing opportunities, partnerships and selective acquisitions, as well as in-house research and development

JW's Pipeline through In-licensing Opportunities, Partnerships and Selective Acquisitions, as well as In-house Research and Development

Hematology: Lead Car-T in hematology cancers leveraging Carteyva® and next generation products. Expand the portfolio for example by enhancing BCMA and other targets by leveraging new technologies, development collaborations, in-licensing or commercial collaborations.

Platform Technologies: Build JW's cell therapy platform including allogeneic, transduction and modules enhancement under new world-class scientific leadership.

Vector Independence: Enhance technical innovation capabilities for LSR/ESD and build vector facility throughout life cycle management.

Solid Tumor: Expand JW's solid tumor pipeline building on current product programs and leveraging new in-house capabilities.

Business Development: Leverage JW's key strengths in commercial, clinical development and manufacturing to attract new technologies, platforms and partnerships to build the solid tumor pipeline and lead in hematology in China and greater Asia.

药明巨诺 JW Therapeutics

Become an Innovation Leader in Cell Immunotherapy

以创新为先导 成为细胞免疫治疗引领者